Northwest Biotherapeutics Inc (NWBO): Total Liabilities
$128.86M
As of 2025-12-31
$110.72M
As of 2026-06-30
-1.9%
3-year compound annual growth
-20.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.86M | +21.9% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $105.71M | +41.1% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $74.92M | -45.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $136.37M | -16.9% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $164.15M | -58.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $395.85M | +610.7% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $55.70M | n/c | 2021-03-31, Balance as of period end |
| 2018-12-31 | $71.83M | -25.3% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $96.20M | +21.2% | 2019-04-02, Balance as of period end |
| 2016-12-31 | $79.41M | +5.2% | 2018-04-17, Balance as of period end |
| 2015-12-31 | $75.47M | -17.5% | 2017-04-17, Balance as of period end |
| 2014-12-31 | $91.48M | n/c | 2016-03-16, Balance as of period end |
| 2013-12-31 | $19.69M | +55.9% | 2015-03-17, Balance as of period end |
| 2012-12-31 | $12.63M | -75.9% | 2014-04-01, Balance as of period end |
| 2011-12-31 | $52.38M | +87.2% | 2013-04-08, Balance as of period end |
| 2010-12-31 | $27.98M | n/a | 2012-04-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.59M | +24.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
Compare NWBO, CPMD, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗